Drugs / JHL1149
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03576651 | Mar → Sep 2018 | — | JHL Biotech, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JHL1149 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03576651 ↗ |
| Route | Intravenous | “Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion” NCT03576651 ↗ |